PHARMACOECONOMIC BENEFITS OF CYTOMEGALOVIRUS INFECTION PROPHYLACTIC STRATEGY FOR RENAL TRANSPLANT RECIPIENTS
https://doi.org/10.15825/1995-1191-2011-3-20-25
Abstract
CMV infection is a major problem in kidney transplantation patients. Valcyte, Cimevene are the first line thera- py of CMV infection. This pharmacoeconomic analysis shown economic benefits of Valcyte prophylaxis tactic compare preemptive strategy.
About the Authors
V. V. Ryazhenov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
S. G. Gorokhova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Инфекции в трансплантологии / Под ред. С.В. Готье. М.–Тверь: Триада, 2010. 384 с.
2. Руководство по трансплантации почки / Под ред. Г.М. Дановича. Тверь: Триада, 2004.
3. Encyclopedia of Virology (Second edition); 1999; Krance R.A. et al. Transplantation and virus infection. P. 1823–1833.
4. Fishman J.A., Emery V., Freeman R., Pascual M. et al. Cytomegalovirus in transplantation – challenging the status // Clin. Transplant. 2007. Vol. 21. P. 149–158.
5. Hodson E.M., Craig J.C., Strippoli G.F.M., Webster A.C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2008, Issue 2.
6. Mauskopf J., Sullivan S., Annemans L. et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices – budget im- pact analysis // Value Health. 2007. Vol. 10. P. 336–347.
7. Kalpoe J.S. et al. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganci- clovir on pre-emptive therapy after renal and renal-pan- creas transplantation // Antivir. Ther. 2005. Vol. 10 (1). P. 119–123.
8. Khoury J.A. et al. Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients AJT 2006. Vol. 6. P. 2134–2143.
9. Kliem V., Fricke L., Wollbrink T. et al. Improvement in Long-Term Renal Graft Survival due to CMV Prophy- laxis with Oral Ganciclovir: Results of a Randomized Clinical Trial AJT 2008. Vol. 8. P. 975–983.
10. Opelz G. CTS 2008 http://ctstransplant.org
11. Paya C.V., Humar A., Dominguez E. et al. Efficacy and safety of valganciclovir vs oral ganciclovir for preven- tion of CMV disease in solid organ transplant recipients PV16000 // Am. J. Transplant. 2004. P. 611–620.
Review
For citations:
Ryazhenov V.V., Gorokhova S.G. PHARMACOECONOMIC BENEFITS OF CYTOMEGALOVIRUS INFECTION PROPHYLACTIC STRATEGY FOR RENAL TRANSPLANT RECIPIENTS. Russian Journal of Transplantology and Artificial Organs. 2011;13(3):20-25. (In Russ.) https://doi.org/10.15825/1995-1191-2011-3-20-25
Views:
751
Email this article 